GAM
APTO

Gotham Asset Management’s Aptose Biosciences, Inc. APTO Stock Holding History

Gotham Asset Management’s Portfolio APTO Stock Details APTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-26
Closed -$69K – 1232
2020
Q1 		$69K Buy
+26
New +$77.5K ﹤0.01% 1019

Other funds holding APTO

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Gotham Asset Management's APTO Position: Q2 2020 in Review

Gotham Asset Management sold out of Aptose Biosciences, Inc. (APTO) in Q2 2020, closing a stake of 26 shares — an estimated $69K sold.

Gotham Asset Management first reported a position in APTO in Q1 2020 and held it in 1 quarter. The position peaked at $69K in Q1 2020. 58 funds tracked by Wall St. Rank hold APTO as of Q2 2020.

  • Gotham Asset Management reported no remaining Aptose Biosciences, Inc. position as of Q2 2020 after selling out during the quarter.
  • Gotham Asset Management sold 26 Aptose Biosciences, Inc. shares in Q2 2020, an estimated $69K.
  • Gotham Asset Management first reported a position in Aptose Biosciences, Inc. in Q1 2020 and held it in 1 quarter.
  • Gotham Asset Management's Aptose Biosciences, Inc. position peaked at $69K in Q1 2020.
  • 58 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q2 2020.

Based on Gotham Asset Management's 13F filing for Q2 2020, filed 13 Aug 2020.